PERSISTENCE TO ORAL AND INJECTABLE MULTIPLE SCLEROSIS DISEASE-MODIFYING THERAPIES

被引：0
|
作者：
Galaznik, A. [1 ]
Rusli, E. [2 ]
Lempernesse, B. [2 ]
Shilnikova, A. [2 ]
Ransom, J. [2 ]
Berger, M. [3 ]
机构：
[1] SHYFT Analyt, Belmont, MA USA
[2] SHYFT Analyt, Waltham, MA USA
[3] Self Employed, New York, NY USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.1362
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND89
引用
收藏
页码：S287 / S287
页数：1
相关论文
共 50 条
  • [1] Persistence to oral disease-modifying therapies in multiple sclerosis patients
    Simona Lattanzi
    Maura Danni
    Ruja Taffi
    Raffaella Cerqua
    Giulia Carlini
    Alessandra Pulcini
    Leandro Provinciali
    Mauro Silvestrini
    Journal of Neurology, 2017, 264 : 2325 - 2329
  • [2] Persistence to oral disease-modifying therapies in multiple sclerosis patients
    Lattanzi, Simona
    Danni, Maura
    Taffi, Ruja
    Cerqua, Raffaella
    Carlini, Giulia
    Pulcini, Alessandra
    Provinciali, Leandro
    Silvestrini, Mauro
    JOURNAL OF NEUROLOGY, 2017, 264 (11) : 2325 - 2329
  • [3] Oral Disease-Modifying Therapies for Multiple Sclerosis
    Kim, Woojun
    Zandona, Manuella Edler
    Kim, Su-Hyun
    Kim, Ho Jin
    JOURNAL OF CLINICAL NEUROLOGY, 2015, 11 (01): : 9 - 19
  • [4] TREATMENT PATTERNS AND PERSISTENCE TO ORAL AND INJECTABLE MULTIPLE SCLEROSIS DISEASE-MODIFYING THERAPIES BETWEEN THE UNITED STATES AND EUROPE
    Galaznik, A.
    Ransom, J.
    Shilnikova, A.
    Rusli, E.
    Lempernesse, B.
    Berger, M.
    VALUE IN HEALTH, 2020, 23 : S277 - S277
  • [5] Fostering adherence to injectable disease-modifying therapies in multiple sclerosis
    Lugaresi, Alessandra
    Rottoli, Maria Rosa
    Patti, Francesco
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2014, 14 (09) : 1029 - 1042
  • [6] Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis
    Eagle, Tessa
    Stuart, Fiona
    Chua, Alicia S.
    LaRussa, Allison
    Leclaire, Kaitlynne
    Cook, Sandra L.
    Chitnis, Tanuja
    Weiner, Howard L.
    Glanz, Bonnie I.
    Healy, Brian C.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 18 : 196 - 201
  • [7] Real-world persistence and adherence of ofatumumab versus oral and injectable disease-modifying therapies in patients with multiple sclerosis
    Hersh, Carrie M.
    Gorritz, Magdaliz
    Chen, Chi-Chang
    Tuly, Rifat
    Gu, Yifan
    Gadkari, Abhijit
    Brown, Brandon
    Shao, Qiujun
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 91
  • [8] The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis
    Kretzschmar, Benedikt
    Pellkofer, Hannah
    Weber, Martin S.
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2016, 16 (04)
  • [9] The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis
    Benedikt Kretzschmar
    Hannah Pellkofer
    Martin S. Weber
    Current Neurology and Neuroscience Reports, 2016, 16
  • [10] Emerging disease-modifying oral therapies for multiple sclerosis
    Losy, Jacek
    Kalinowska-Lyszczarz, Alicja
    JOURNAL OF NEUROIMMUNOLOGY, 2011, 231 (1-2) : 15 - 22
12345